Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adrenergic beta-1 receptor (ADRB1)
- Target
- ADRB1
- Molecular classification
- G protein-coupled receptor (GPCR), Receptor, Adrenergic receptor family
01
Overview
The Adrenergic beta-1 receptor is a transmembrane protein of the large G protein-coupled receptor (GPCR) family, predominantly expressed in cardiac tissue. It mediates the stimulatory actions of endogenous catecholamines (epinephrine and norepinephrine) via coupling to Gs proteins, leading to increased heart rate, contractility, and renin release. Selective antagonists (beta-1 blockers) are widely used in medicine to treat hypertension, heart failure, angina, myocardial infarction, and arrhythmias by dampening sympathetic output to the heart. Selectivity for the beta-1 subtype helps minimize adverse effects in airway and metabolic regulation. This target’s role in cardiovascular homeostasis and disease makes it a critical focus for both pharmacology research and clinical therapy.
- Other names
- Beta-1 adrenergic receptorβ1-adrenoceptorβ1ARADRB1
02
Mechanism of action
Agonists: Bind and activate ADRB1, increasing heart rate and contractility. Antagonists (beta blockers): Bind and inhibit ADRB1, reducing heart rate, contractility, blood pressure, and oxygen demand.
03
Biological functions
Signal transductionRegulation of heart rate and cardiac contractilityStimulation of renin release (in kidneys)Regulation of lipolysis (fat metabolism)
04
Disease associations
Cardiovascular disease (hypertension, heart failure, arrhythmias, myocardial infarction)Other (role in some tumors and glaucoma; rarely, psychiatric implications with antagonists)
05
Safety considerations
Nonselective beta blocker use in asthmatic patients can cause life-threatening bronchospasm due to cross-reactivity with beta-2 adrenergic receptorsSide effects: bradycardia, hypotension, fatigue, decreased peripheral circulation, acute heart failure exacerbationPotential for metabolic disturbances and masking signs of hypoglycemia in diabetics
06
Interacting drugs
Acebutolol
16 more in the full profile.
07
Biomarkers
ADRB1 genetic variants may affect response to beta blockers and heart disease outcomes (clinical relevance evolving; not standard yet)
Beyond the preview
Go deeper on Adrenergic beta-1 receptor (ADRB1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adrenergic beta-1 receptor (ADRB1).